COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study-Reference-Cited by-同舟云学术

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study

Published:2022-11 Issue: Volume:175 Page:1-10
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Lee Lennard Y.W.,Ionescu Maria C.,Starkey Thomas,Little Martin^ORCID,Tilby Michael^ORCID,Tripathy Arvind R.,Mckenzie Hayley S.,Al-Hajji Youssra,Appanna Nathan,Barnard Matthew,Benny Liza^ORCID,Burnett Alexander,Cattell Emma L.,Clark James J.,Khan Sam,Ghafoor Qamar,Panneerselvam Hari,Illsley George,Harper-Wynne Catherine,Hattersley Rosie J.,Lee Alvin JX.^ORCID,Lomas Oliver,Liu Justin KH.^ORCID,McCauley Amanda,Pang Matthew,Pascoe Jennifer S.,Platt James R.,Patel Grisma,Patel Vijay,Potter Vanessa A.,Randle Amelia,Rigg Anne S.,Robinson Tim M.,Roques Tom W.,Roux René L.,Rozmanowski Stefan,Taylor Harriet,Tuthill Mark H.,Watts Isabella^ORCID,Williams Sarah,Beggs Andrew^ORCID,Iveson Tim^ORCID,Lee Siow M.,Middleton Gary,Middleton Mark,Protheroe Andrew,Fittall Matthew W.,Fowler Tom,Johnson Peter,Kinloch Emma,Lam Emily,Murphy Gillian,Rhodes Malcolm,Robinson Kate,Swarup Sanskriti,Bernhardt Keeley,Bytyci Jola,Ying Yuxin,Johal Sukhmunni,Sheehan Remarez

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study;Lee;Lancet,2020

2. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study;Kuderer;Lancet,2020

3. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study;Lee;J: Lancet Oncol,2020

4. JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022. GOV.UK https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022.

5. Third primary COVID-19 vaccine dose for people who are immunosuppressed: JCVI advice. GOV.UK https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccination against COVID-19 in a post-pandemic era;COVID-19: An Update;2024-09-01

2. Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain;Nature Communications;2024-06-19

3. Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England;BMC Medicine;2024-06-10

4. Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study;The Lancet Oncology;2024-05

5. Immunocompromised individuals are at increased risk of COVID‐19 breakthrough infection, hospitalization, and death in the post‐vaccination era: A systematic review;Immunity, Inflammation and Disease;2024-04